Research analysts at Needham & Company LLC initiated coverage on shares of InflaRx (NASDAQ:IFRX – Get Free Report) in a report issued on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 282.78% from the company’s previous close.
Several other research firms have also commented on IFRX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Wednesday, June 24th. Zacks Research lowered InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 25th. Finally, Cantor Fitzgerald boosted their price objective on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, InflaRx presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.43.
Get Our Latest Analysis on IFRX
InflaRx Stock Performance
InflaRx (NASDAQ:IFRX – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Equities research analysts predict that InflaRx will post -0.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On InflaRx
Institutional investors and hedge funds have recently modified their holdings of the business. Montanova Capital LLC grew its holdings in InflaRx by 189.1% in the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock valued at $51,372,000 after purchasing an additional 15,000,000 shares during the period. Spruce Street Capital LP purchased a new position in shares of InflaRx during the 2nd quarter valued at approximately $11,988,924. ADAR1 Capital Management LLC acquired a new stake in InflaRx in the 2nd quarter valued at $6,720,000. Bank of America Corp DE purchased a new stake in InflaRx in the 3rd quarter worth $3,316,000. Finally, Suvretta Capital Management LLC raised its position in InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after acquiring an additional 1,450,000 shares during the period. Hedge funds and other institutional investors own 42.39% of the company’s stock.
About InflaRx
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
See Also
- Five stocks we like better than InflaRx
- Digging for Value: Alpha Metallurgical Resources Insider Buys Big
- Smart Money Shifts: U.S. Bancorp Pairs Tech With Yield
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
